Axsome Therapeutics (AXSM) News Today $103.98 -1.09 (-1.04%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$106.90 +2.92 (+2.81%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AXSM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Axsome Therapeutics, Inc.: Axsome Therapeutics Settles SUNOSI (solriamfetol) Patent Litigation with Hetero Labs Ltd.May 28 at 1:36 AM | finanznachrichten.deAxsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.May 27 at 7:00 AM | globenewswire.comTFG Asset Management GP Ltd Makes New $3.49 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)TFG Asset Management GP Ltd purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 41,250 shares of the company's stock, valMay 27 at 6:03 AM | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Nuveen Asset Management LLCNuveen Asset Management LLC raised its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 118.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 221,202 shares of the company's stock after buying anMay 26 at 3:54 AM | marketbeat.comProShare Advisors LLC Raises Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)ProShare Advisors LLC raised its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 30.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,664 shares of the company's stock after acquiring an additMay 25 at 4:04 AM | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from HC WainwrightMay 25 at 2:11 AM | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $180.00 price target on shares of Axsome Therapeutics in a report on Thursday.May 24, 2025 | marketbeat.com3 High-Flying Stocks That Could Soar Even MoreMay 24, 2025 | fool.comCaptrust Financial Advisors Has $250,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Captrust Financial Advisors reduced its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 48.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,953 shares of the company's stock after sMay 24, 2025 | marketbeat.comWoodline Partners LP Acquires 109,872 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Woodline Partners LP lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 36.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 408,441 shares of the company's stock after purchasing an additional 109,872 shares during the period. WoodMay 23, 2025 | marketbeat.comBrokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) Price Target at $172.14May 23, 2025 | americanbankingnews.comNationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fundMay 22, 2025 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of "Buy" by BrokeragesShares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) have received a consensus rating of "Buy" from the fifteen research firms that are covering the stock, MarketBeat reports. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating on the coMay 22, 2025 | marketbeat.comMark Coleman Sells 3,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) StockMay 21, 2025 | insidertrades.comTFG Asset Management GP Ltd Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)TFG Asset Management GP Ltd bought a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 41,250 shares of the company's stock, vaMay 20, 2025 | marketbeat.comMan Group plc Acquires New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Man Group plc acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 163,388 shares of the company's stock, valued at approximately $13,824,000. Man Group pMay 20, 2025 | marketbeat.comDeutsche Bank AG Purchases 32,789 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Deutsche Bank AG raised its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 37.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 120,547 shares of the company's stock after purchasing an additiMay 19, 2025 | marketbeat.comRTW Investments LP Cuts Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)RTW Investments LP lessened its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 3.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,051,365 shares of the company's stock after sellingMay 18, 2025 | marketbeat.comPoint72 Europe London LLP Grows Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Point72 Europe London LLP boosted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 20.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 41,734 shares of the company's stock after purchasing an additional 7,164 shares duMay 17, 2025 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Upgraded by Cantor Fitzgerald to Strong-Buy RatingCantor Fitzgerald raised Axsome Therapeutics to a "strong-buy" rating in a research report on Wednesday.May 17, 2025 | marketbeat.comComerica Bank Cuts Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Comerica Bank trimmed its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 32.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,374 shares of the company's stock after selling 3,5May 17, 2025 | marketbeat.comAxsome Therapeutics (AXSM) Receives a Buy from Bank of America SecuritiesMay 16, 2025 | theglobeandmail.comMPM Bioimpact LLC Invests $4.23 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM)MPM Bioimpact LLC acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 50,000 shares of the company's stock, valued at approximately $4,230,000.May 16, 2025 | marketbeat.comAxsome Enters $570 Mln Term Loan And Revolving Credit Facility With BlackstoneMay 15, 2025 | nasdaq.comLazard Asset Management LLC Raises Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Lazard Asset Management LLC grew its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 525.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 537,669 shares of the company's stock aftMay 15, 2025 | marketbeat.comIs Axsome Therapeutics Stock Worth the Risk? A Comprehensive AnalysisMay 14, 2025 | fool.comAxsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with BlackstoneMay 13, 2025 | globenewswire.comBNP Paribas Financial Markets Has $15.71 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)BNP Paribas Financial Markets increased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 1,251.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 185,661 shares of the compMay 13, 2025 | marketbeat.comNorthern Trust Corp Acquires 69,918 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Northern Trust Corp lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 21.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 402,500 shares of the company's stock after purchasing an additional 69,918 shares during the quarter. NMay 13, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Forecast for AXSM EarningsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a report issued on Wednesday, May 7th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earMay 13, 2025 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Frontier Capital Management Co. LLCFrontier Capital Management Co. LLC lessened its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 56.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,768 shares of the compaMay 12, 2025 | marketbeat.com3 Monster Stocks in the MakingMay 11, 2025 | fool.comBalyasny Asset Management L.P. Increases Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Balyasny Asset Management L.P. raised its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 171.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 181,213 shares of the company's stock after purchMay 11, 2025 | marketbeat.comQ2 EPS Forecast for Axsome Therapeutics Boosted by AnalystAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a report issued on Monday, May 5th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($1.21)May 10, 2025 | marketbeat.comQ2 EPS Forecast for Axsome Therapeutics Lifted by AnalystAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at William Blair increased their Q2 2025 earnings per share estimates for shares of Axsome Therapeutics in a research note issued on Monday, May 5th. William Blair analyst M. Minter now anticipates that the companyMay 10, 2025 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Fairmount Funds Management LLCFairmount Funds Management LLC reduced its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 37.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,468,983 shares of the company's stMay 10, 2025 | marketbeat.comCubist Systematic Strategies LLC Purchases New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Cubist Systematic Strategies LLC bought a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 116,937 shares of the company's stock, valued at approximately $9,894,000.May 10, 2025 | marketbeat.comAxsome Therapeutics (AXSM) Receives a Buy from GuggenheimMay 9, 2025 | theglobeandmail.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $180.00 at HC WainwrightHC Wainwright reduced their target price on Axsome Therapeutics from $200.00 to $180.00 and set a "buy" rating for the company in a report on Wednesday.May 9, 2025 | marketbeat.comWilliam Blair Analysts Increase Earnings Estimates for AXSMAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at William Blair raised their FY2028 earnings per share estimates for shares of Axsome Therapeutics in a research note issued to investors on Monday, May 5th. William Blair analyst M. Minter now forecasts that the company willMay 9, 2025 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 12.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 31,228 shares of the company's stock after acquiring an additional 3,366 shares during the pMay 9, 2025 | marketbeat.comRobert W. Baird Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) StockRobert W. Baird increased their price objective on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the stock an "outperform" rating in a research note on Tuesday.May 8, 2025 | marketbeat.comAnalysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its First-Quarter ResultsMay 8, 2025 | finance.yahoo.comBrevan Howard Capital Management LP Boosts Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Brevan Howard Capital Management LP increased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 169.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,748 shares of the companyMay 8, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Has $2.15 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Schonfeld Strategic Advisors LLC lessened its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 69.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,380 shares of the company's stock after selling 56,617 shares duMay 8, 2025 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Shares Up 5.6% on Better-Than-Expected EarningsAxsome Therapeutics (NASDAQ:AXSM) Shares Up 5.6% After Earnings BeatMay 7, 2025 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Issues Quarterly Earnings ResultsAxsome Therapeutics (NASDAQ:AXSM - Get Free Report) issued its earnings results on Monday. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.43. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%.May 7, 2025 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Issues Earnings Results, Beats Expectations By $0.43 EPSAxsome Therapeutics (NASDAQ:AXSM - Get Free Report) announced its earnings results on Monday. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.43. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%.May 7, 2025 | marketbeat.comBridgefront Capital LLC Purchases Shares of 10,555 Axsome Therapeutics, Inc. (NASDAQ:AXSM)Bridgefront Capital LLC acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,555 shares of the company's stock, valued at approximately $893,000. Several oMay 7, 2025 | marketbeat.com1AXSM : Axsome Therapeutics Clocks Around 60% Topline Growth In Q1May 7, 2025 | benzinga.com Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Media Mentions By Week AXSM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼1.021.03▲Average Medical News Sentiment AXSM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼1510▲AXSM Articles Average Week Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TEVA News SMMT News ITCI News GMAB News RDY News MRNA News ASND News VTRS News QGEN News ROIV News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AXSM Stock Free AXSM Stock Alerts